Drug
Famitinib clinical trials
Also written SHR-1020.
Includes 7 studies of Famitinib malate.
- studies test it
- 53
- open now
- 21
- in phase 3
- 9
- first study started
- 2009
Keep track of what changes. Save the famitinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
53 studies that test it; most in 2021 (10)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 4 |
| 2012 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 7 |
| 2021 | 10 |
| 2022 | 6 |
| 2023 | 4 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 38
- Phase 3
- 9
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 24 · Other 29
Jiangsu HengRui Medicine Co., Ltd. (24) · Fudan University (11) · Tianjin Medical University Cancer Institute and Hospital (2) · Qian Chu (1) · The First Affiliated Hospital of Zhengzhou University (1) · Hunan Cancer Hospital (1) · Shanghai Zhongshan Hospital (1) · Qinglei Gao (1)
Often tested with
Tested in the same studies.
Camrelizumab (18) · SHR-1701 (7) · Paclitaxel (5) · Trastuzumab rezetecan (5) · Adebrelimab (5) · Dalpiciclib (5) · Albumin-Bound Paclitaxel (4) · Everolimus (4)
Studies
Open first, then newest update. How each study uses famitinib is read from its arms, and is right about nine times in ten.
Testing it · 53
- Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion Chemotherapy for Locally Advanced Intrahepatic Cholangiocarcinoma: A Multicenter, Single-Arm, Exploratory Phase II TrialRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07847710Written as Famitinib malate
- Retlirafusp Alfa Combined With Famitinib, Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Unresectable Pancreatic CancerNot yet recruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07814859Written as Famitinib
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as Famitinib
- Adebrelimab With Famitinib and Chemotherapy as Neoadjuvant Therapy for ESCCRecruitingPhase 2First Affiliated Hospital Xi'an Jiaotong UniversityNCT07796113Written as Adebrelimab + Famitinib + Chemotherapy
- Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingPhase 1/2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07662681Written as camrelizumab with famitinib
- Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingPhase 2Hunan Cancer HospitalNCT07627620Written as Famitinib Malate
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Famitinib
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as A2: SHR-A1811 with Camrelizumab with famitinib
- Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal MelanomaNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07517653Written as Famitinib
- Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 SubtypeNot yet recruitingPhase 3Fudan UniversityNCT07382687Written as Famitinib+SHR-A1811
- A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian CancerNot yet recruitingPhase 2Qinglei GaoNCT07355010Written as Famitinib
- A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical CancerNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07143292Written as Famitinib + Camrelizumab
- Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma.Not yet recruitingPhase 2Fudan UniversityNCT07147088Written as Famitinib
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as Famitinib
- Adibelimab, Famitinib and Chemotherapy for Advanced NSCLC After PD-1 Inhibitor FailureNot yet recruitingPhase 2Second Affiliated Hospital of Xi'an Jiaotong UniversityNCT06336954Written as Adibelimab
- Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingPhase 1/2Baohui HanNCT06332950Written as Adebrelimab, Irinotecan Liposome (II), Famitinib
- A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.Not yet recruitingPhase 2Harbin Medical UniversityNCT06306560Written as famitinib
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)RecruitingPhase 3Fudan UniversityNCT05999149Written as Camrelizumab Plus Chemotherapy and Famitinib
- Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingPhase 3Fudan UniversityNCT05760378Written as Famitinib
- Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid CancerNot yet recruitingPhase 2Ruijin HospitalNCT06146985Written as 20 mg Famitinib & 1200 mg Adebrelimab
See all 53 studies that test famitinib →
Given in every arm · 3 — famitinib is usual care beside what is tested
- Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± CamrelizumabRecruitingPhase 2Fudan UniversityNCT06516289Written as Famitinib
- A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid TumorsStatus unknownPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT04679038Written as Famitinib
- Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced OsteosarcomaWithdrawnPhase 1/2Peking University People's HospitalNCT04044378Written as Famitinib
Codes
What other systems call famitinib · ClinicalTrials.gg INT006373
- MeSH (NLM) C584390famitinibOne source NLM
- UNII (FDA) 768FW21J3LFAMITINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27077275famitinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C97512FamitinibOne source FDA
- DrugBank DB11741One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C584390 | famitinib | One source NLM |
| UNII (FDA) | 768FW21J3L | FAMITINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27077275 | famitinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C97512 | Famitinib | One source FDA |
| DrugBank | DB11741 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.